Ruxolitinib: A New Treatment for Myelofibrosis
Ruxolitinib: A New Treatment for Myelofibrosis
复制标题
DOI：
10.1188/13.cjon.312-318
复制
发表时间：
2013-06-01
影响因子：
1.1
通讯作者：
Schneider, Susan M.
中科院分区：
文献类型：
--
作者：
Lowery, Emily W.;Schneider, Susan M.
骨髓纤维化(MF)是一种以骨髓纤维化和造血改变为特征的血癌。虽然MF的患病率较低，但其严重的症状对患者的生活质量有显著的负面影响，并且其转化为白血病的能力增加了发病率。传统的药物治疗能适度缓解症状，但异基因干细胞移植一直是唯一能够影响MF自然病史的治疗方法。Ruxolitinib(Jakafi(R))是一种新的靶向疗法，用于治疗中高风险ME患者。尽管关于ruxolitinib影响生存或诱导缓解的能力的研究存在矛盾，但研究表明，它在症状管理方面有显著改善。然而，鲁索利替尼有一些潜在的危及生命的不良反应。本文回顾了Ruxolitinib，讨论了它的风险和益处，并描述了肿瘤科护士在教育、监测和支持中的重要作用。
Myelofibrosis (MF) is a blood cancer characterized by fibrotic bone marrow and altered hematopoiesis. Although the prevalence of MF is low, its severe symptoms have a significantly negative impact on patient quality of life, and its ability to transform into leukemia increases morbidity. Conventional drug therapies provide modest symptom palliation, but allogeneic stem cell transplantation has been the only treatment capable of affecting MF's natural history. Ruxolitinib (Jakafi (R)) is a new targeted therapy indicated to treat patients with intermediate- and high-risk ME Although the research is conflicted regarding ruxolitinib's ability to affect survival or induce remission, studies show that it offers dramatic improvements in symptom management. However, ruxolitinib carries some potentially life-threatening adverse effects. This article reviews ruxolitinib, discusses its risks and benefits, and describes the vital role of oncology nurses in education, monitoring, and support.